E
Eric J. Topol
Researcher at Scripps Health
Publications - 1406
Citations - 162373
Eric J. Topol is an academic researcher from Scripps Health. The author has contributed to research in topics: Myocardial infarction & Angioplasty. The author has an hindex of 193, co-authored 1373 publications receiving 151025 citations. Previous affiliations of Eric J. Topol include Loyola University Chicago & Cleveland Clinic.
Papers
More filters
Posted ContentDOI
A Whole Blood Molecular Signature for Acute Myocardial Infarction
Evan D. Muse,Eric R. Kramer,Haiying Wang,Paddy M. Barrett,Fereshteh Parviz,Mark Novotny,Roger S. Lasken,Timothy A. Jatkoe,Glenn Oliveira,Hongfan Peng,Jerry Lu,Marc C Connelly,Kurt G. Schilling,Chandra Rao,Ali Torkamani,Eric J. Topol +15 more
TL;DR: It is suggested that a whole blood CEC-derived molecular signature identifies patients with AMI and sets the framework to potentially identify the earlier stages of an impending cardiac event where conventional biomarkers indicative of myonecrosis remain undetected.
Journal ArticleDOI
Molecular genetics of atrial fibrillation
Samir Damani,Eric J. Topol +1 more
TL;DR: The Paired-like homeodomain transcription factor 2 (PITX2) gene, which is involved in embryonic cardiac development, has now been identified as the causal variant for the 4q25 susceptibility locus.
Long-term Efficacy of Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade vs Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Revascularization
A. Michael Lincoff,Neal S. Kleiman,Dean J. Kereiakes,Frederick Feit,John A. Bittl,J. Daniel Jackman,Ian J. Sarembock,David Cohen,Douglas Spriggs,Ramin Ebrahimi,Gadi Keren,Jeffrey Carr,Eric A. Cohen,Amadeo Betriu,Walter Desmet,Wolfgang Rutsch,Robert G. Wilcox,Pim J. de Feyter,Alec Vahanian,Eric J. Topol +19 more
TL;DR: Nonsignificant trends toward lower 1-year mortality with bivalirudin were present in all patient subgroups analyzed and were of greatest magnitude among high-risk patients.
Journal ArticleDOI
Relationship Between Baseline Inflammatory Markers, Antiplatelet Therapy, and Adverse Cardiac Events After Percutaneous Coronary Intervention An Analysis From the Clopidogrel for the Reduction of Events During Observation Trial
Kristofer Dosh,Peter B. Berger,Steven P. Marso,Fredrick Van Lente,Danielle M. Brennan,Richard Charnigo,Eric J. Topol,Steven R. Steinhubl +7 more
TL;DR: Patients undergoing nonurgent percutaneous coronary intervention who have elevated hs-CRP and PAPP-A have an increased incidence of adverse cardiovascular events and the clinical benefit of adding clopidogrel to aspirin seems greater in those with increased levels of these inflammatory biomarkers.
Journal ArticleDOI
Clinical angiographic and histologic correlates of eetasia after directional coronary atherectomy
Nicoletta De Cesare,Jeffrey J. Popma,David R. Holmes,Ronald J.L. Dick,Patrick L. Whitlow,Spencer B. King,Cass A. Pinkerton,Dean J. Kereiakes,Eric J. Topol,Christian C. Haudenschild,Stephen G. Ellis +10 more
TL;DR: It is concluded that excision beyond the normal arterial lumen may occur after directional coronary atherectomy, related, in part, to angiographic and procedural features noted at the time of atheresctomy.